Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
AstraZeneca (LSE:AZN) shares have been in focus after fresh collaboration news, with investors weighing how new research alliances and recent regulatory milestones might feed into the company’s large, oncology heavy product portfolio.
See our latest analysis for AstraZeneca.
The recent siRNA and oncology collaborations come as AstraZeneca’s share price sits at £143.64, with a 30 day share price return of 3.65% but a 90 day share price return that has declined 5.60%. The 1 year total shareholder return of 41.34% and 5 year total shareholder return of 82.23% point to momentum that has built over a longer horizon.
If this kind of partnership driven growth story interests you, it could be a good time to scan the market for other healthcare focused AI opportunities using the 5 healthcare AI stocks
After a strong 1 year run and a recent pullback over 90 days, AstraZeneca now sits at £143.64 with fresh oncology and siRNA deals in hand. Does the current balance of risk and reward still lean towards buyers?
Most Popular Narrative: 12.9% Undervalued
The most followed AstraZeneca narrative suggests a fair value of £164.85 against the current £143.64 share price, with that gap tied directly to expectations for the drug pipeline, margins and long term earnings power.
The company’s robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches over the next several years. Management estimates these new medicines could generate $10+ billion in peak risk-adjusted revenue, directly supporting both long-term high-margin revenue growth and future earnings expansion.
Want to see what sits behind that blockbuster revenue ambition and higher margin outlook? The narrative leans on specific growth, profitability and valuation assumptions that could reshape how you view AstraZeneca.
Result: Fair Value of £164.85 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, investors still need to watch for pricing pressure in key markets and the reliance on blockbuster drugs, as both factors could undermine the AstraZeneca undervaluation case.
Find out about the key risks to this AstraZeneca narrative.
Another View: AstraZeneca Through a P/E Lens
While the most popular AstraZeneca narrative leans on cash flow and long term earnings power, the current P/E ratio of 28.7x tells a different story. It sits well above both the peer average of 12.3x and the fair ratio estimate of 39.6x. This suggests investors are already paying a premium, even if the market could move toward a higher multiple over time. That leaves you weighing whether this premium reflects resilience or adds valuation risk if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
LSE:AZN P/E Ratio as at Jul 2026 Next Steps
With AstraZeneca attracting both optimism and caution in this article, consider acting promptly and weigh the full picture for yourself by reviewing the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond AstraZeneca?
If the AstraZeneca story has sharpened your interest, now is the moment to broaden your watchlist and uncover other stocks that could fit your portfolio goals.
Spot potential turnarounds early by checking out 44 elite penny stocks with strong financials that already pair small share prices with stronger underlying financials.
Hunt for value oriented opportunities using the 9 high quality undervalued stocks that highlights companies combining quality fundamentals with prices that may sit below their assessed worth.
Strengthen your income stream by reviewing the 3 dividend fortresses featuring higher yielding stocks that also prioritise stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AZN.L.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com